Skip to main content
. 2022 Nov 11;14(22):5545. doi: 10.3390/cancers14225545

Table 1.

Potential multi-omics base Genomics biomarkers in CRC.

Biomarker Sample Type Change Application References
CBX8, CD96 datasets downregulated diagnostic [54]
MTUS1 tissue downregulated diagnostic and prognostic [55]
SDC2, NDRG4 stool upregulated Screening [56]
SOX21 stool upregulated diagnostic [57]
BDNF, PTGS2, GSK3B and CTNNB1 tissue upregulated prognostic and diagnostic [33]
HPGD tissue downregulated prognostic and diagnostic [33]
YWHAB, MCM4, and FBXO46 datasets overexpress prognostic [58]
DPP72 datasets lower expression prognostic [58]
SDC2, TFPI2 stool hypermethylated screening [59]
SNORD15B, SNORA5C tissue upregulated diagnostic and prognostic [60]
GALR1 tissue hypermethylation screening [61]
LRRC19 datasets downregulated prognosis [62]
KRAS, BRAF, PIK3CA tissue mutation detection [63]